Renal tumors account for 3–4% of all malignant tumors in adults; 80–90% of these are renal cell carcinomas, which are unilateral in 97% of patients and bilateral in 3%. Roughly 15 500 patients were given the diagnosis of renal cell...

Data are limited regarding routine use of everolimus after initial vascular endothelial growth factor (VEGF)–targeted therapy. The aim of this prospective, noninterventional, observational study was to assess efficacy and safety of everolimus after initial VEGF-targeted treatment in patients with metastatic renal cell carcinoma (mRCC) in routine clinical settings. Everolimus was administered per routine clinical practice. Patients with mRCC of any histology from 116 active sites in Germany were included. The main objective was to determine everolimus efficacy in time to progression (TTP). Progression-free survival (PFS), treatment duration, tumor response, adherence to everolimus regimen, treatment after everolimus, and safety were also assessed. In the total population (N = 334), median follow-up was 5.2 months (range, 0–32 months). Median treatment duration (safety population, n = 318) was 6.5 months (95% confidence interval [CI], 5–8 months). Median TTP and median PFS were similar in populations investigated. In patients who received everolimus as second-line treatment (n = 211), median (95% CI) TTP was 7.1 months (5–9 months) and median PFS was 6.9 months (5–9 months). Commonly reported adverse events (safety population, n = 318) were dyspnea (17%), anemia (15%), and fatigue (12%). Limitations of the noninterventional design should be considered. This study reflects routine clinical use of everolimus in a large sample of patients with mRCC. Favorable efficacy and safety were seen for everolimus after previous therapy with one VEGF-targeted agent. Results of this study confirm everolimus as one of the standard options in second-line therapy for patients with mRCC. Novartis study code, CRAD001LD27: VFA registry for noninterventional studies ( http://www.vfa.de/de/forschung/nisdb/ ).

Die „aktuelle“ Krebsregistermeldung, wie sie im Jahr 2015 in Deutschland verpflichtend eingeführt wurde, hat ihren Ausgangpunkt auch im Nationalen Krebsplan aus dem Jahr 2008. Weitere Meilensteine sind das Bundeskrebsregisterdatengesetz (2009), das Krebsfrüherkennungs- und -registergesetz (2013), der einheitliche Onkologische Basisdatensatz (2014/2021) mit den Modulen (z.B. Modul Prostatakarzinom 2017) sowie das Gesetz zur Zusammenführung von Krebsregisterdaten (2021). Deutsche Uro-Onkologen (d-uo) hatten bereits Anfang 2017 die Idee, eine Dokumentationsplattform zu konzipieren, mit der die Mitglieder von d-uo einerseits die Meldung an das Krebsregister ermöglicht wird und andererseits Daten in die eigene Datenbank von d-uo überführt werden können – ohne doppelten Aufwand. Das Krebsregister vergütet die Erstmeldung einer Tumorerkrankung mit 18€. Als weiterhin einziger Anbieter vergütet d-uo seinen Mitgliedern den mit der zusätzlichen Meldung an d-uo verbunden Dokumentationsaufwand mit weiteren 18€. Zusätzlich zum Onkologischen Basisdatensatz wurden weitere Parameter von d-uo definiert. Diese Daten werden im Rahmen der sogenannten VERSUS-Studie erhoben, ausgewertet und interpretiert. Die Erkenntnis, dass die Parameter des Basisdatensatzes in ihrer Aussagefähigkeit limitiert sind, hat seitens d-uo zur Etablierung der beiden Nationalen Register Urothelkarzinom (UroNAT) und Prostatakarzinom (ProNAT) geführt. Damit unterstreicht d-uo seine führende Position in der uro-onkologischen Versorgungsforschung in Deutschland. The current cancer registry notification, which was introduced in Germany as a mandatory institution in 2015, has its starting point in the National Cancer Plan of 2008. Other milestones include the Federal Cancer Registry Data Act (2009), the Cancer Early Detection and Registry Act (2013), the Uniform Oncological Basic Data Set (2014/2021) with its modules (e.g. the module prostate carcinoma 2017) as well as the Cancer Registry Data Merger Act (2021). At the beginning of 2017, the German Society of Uro-Oncologists (d-uo) had the idea of designing a documentation platform that would enable d-uo members to report to the cancer registry and transfer data to d-uo’s own database – without a double effort. The cancer registry reimburses the first notification of a tumour with € 18. As the only provider, d-uo reimburses its members for the documentation effort associated with the additional notification to d-uo with a further € 18. In addition to the basic oncological data set, further parameters were defined by d-uo. This data is collected, evaluated and interpreted as part of the VERSUS study. The realisation that the parameters of the basic data set are limited in their informative value led d-uo to establish the two national registries for urothelial carcinoma (UroNAT) and prostate carcinoma (ProNAT). This underscores d-uo’s leading position in uro-oncological healthcare research in Germany. Received: 13 March 2023 Accepted after revision: 28 March 2023 Article published online: 24 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

The approval of tyrosine kinase inhibitors and checkpoint inhibitors represented a remarkable progression in the therapeutic landscape for the treatment of metastatic renal cell carcinoma (mRCC). Yet, in the ever-evolving landscape of mRCC treatment, real-world data on these agents, including pazopanib, are scarce. The non-interventional PAZOREAL study investigated the effectiveness and safety of pazopanib (first-line), nivolumab (second-line), and everolimus (second- and third-line) in a real-life setting. The multicentric study included 376 mRCC patients who received first-line treatment with pazopanib and assessed time on the drug (primary endpoint), overall survival, best responses, disease control rates, as well as safety signals and health-related quality of life. The median overall time on the drug was 10.0 months, with first-line pazopanib having a median time on drug of 6.3 months. The median overall survival was 35.9 months. The disease control rate for first-line pazopanib was 56.9%. No new safety signals were detected. PAZOREAL provides valuable real-world data for first-line treatment with pazopanib.